# MAX-10181 Given Orally to Patients With Advanced Solid Tumor

> **NCT04122339** · PHASE1 · UNKNOWN · sponsor: **Maxinovel Pty., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** MAX-10181

## Key facts

- **NCT ID:** NCT04122339
- **Lead sponsor:** Maxinovel Pty., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-11
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04122339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04122339, "MAX-10181 Given Orally to Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT04122339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*